Emergent Biosolutions Inc (EBS) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Emergent Biosolutions Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Emergent Biosolutions Inc 's ROA in the second quarter of 2026?
Emergent Biosolutions Inc recorded a cumulative net loss of $-177 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -12.79%.
However, within the Healthcare sector 326 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 1684 to 2622.
In a pivotal moment for Emergent BioSolutions Inc. (NYSE:EBS), the company has finalized the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a transaction valued at approximately $36.5 million. This sale, announced on March 19, 2025, marks a significant shift in Emergent’s operational strategy as it refocuses on its core competencies within the biopharmaceutical sector. The proceeds from this transaction, albeit subject to customary post-closing adjustments, introduce a much-needed influx of capital for the company at a time when it is grappling with broader market challenges.Earlier, on January 8, 2025, Emergent BioSolutions reported securing a $20 million contract modification with the U.S. Department of Defense (DoD) for the supply of BioThrax (Anthrax Vaccine Adsorbed). This contract serves as a testament to the federal government s commitment to bolstering national biodefense strategies in light of emerging biological threats. BioThrax is notably the only FDA-licensed vaccine for anthrax prevention, underscoring its critical role within the nation’s public health arsenal against potential bioterrorism.
Emergent BioSolutions Inc (NYSE: EBS) has seen a commendable performance this month, with shares reflecting a 0.55% increase, contrasting with the broader market trends. Several developments within the company and its external engagements have likely contributed to this favorable outcome.One significant factor has been Emergent BioSolutions’ proactive approach to addressing the opioid epidemic. Recently, Pro Football Hall of Famer Emmitt Smith partnered with the company to promote awareness of opioid overdoses through a new educational video. This initiative not only aligns with the company’s mission but also positions it as a responsible leader in public health advocacy. The visibility and engagement generated by such collaborations can enhance the company’s reputation, thereby positively impacting investor sentiment.
Comment on EBS's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 3.99 % compared to prior year, due to annual net income growth of % to $52.60 million, and due to decline of value in Emergent Biosolutions Inc 's assets by -5.12 % to $1,318.60 million, compared to $1,318.60 a year before.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
